RecruitingNCT05541367

Estrogen Receptor (ER) PET/CT Imaging in Breast Cancer


Sponsor

Tongji Hospital

Enrollment

80 participants

Start Date

Dec 31, 2021

Study Type

OBSERVATIONAL

Conditions

Summary

18F-Fluoroestradiol (18F-FES) is an estrogen receptor-targeting positron emission tomography tracer with high sensitivity and specificity for the detection of estrogen receptor(ER)-positive tumors . 18F-FES has been used as a predictive biomarker to demonstrate estrogen receptor heterogeneity , to evaluate the pharmacokinetics of estrogen receptor-targeted drugs , to measure residual estrogen receptors during endocrine therapy and to determine biologically optimal doses of novel estrogen receptor-targeted drugs .This study aimes to explore the efficacy of 18F-FES PET/CT in evaluating the expression levels of ER in primary and metastatic breast cancer patients.


Eligibility

Min Age: 18 Years

Inclusion Criteria3

  • More than 18 years old
  • Patients with pathologically confirmed breast cancer
  • Sign the informed consent form

Exclusion Criteria2

  • Pregnant women
  • Severe underlying diseases that cannot cooperate with PET examination

Locations(1)

TongjiHospital

Wuhan, Hubei, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05541367


Related Trials